Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves DARZALEX for relapsed multiple myeloma
In July 2016, daratumumab was granted a Breakthrough Therapy Designation (BTD) in this patient population. In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to
In July 2016, daratumumab was granted a Breakthrough Therapy Designation (BTD) in this patient population. In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to
This study will evaluate pharmacokinetics, safety and tolerability of DITEST in the target patient group of males with hypogonadism (Clinical Trials ID NCT02966652). Diurnal CEO Martin Whitaker said: "The
The OPTICORE coating technology comprises two trigger systems and an accelerator to allow targeted drug release in the large intestine to improve local and/or systemic drug bioavailability. The inner
Published in PLoS Pathogens, is the description of a neonatal mouse model that provides a platform for potentially improving and expediting studies to understand the causes and effects
Under the terms of the agreement, Celgene committed $9 million to PharmAkea to extend the collaboration for 9 months. PharmAkea announced the original 3-year collaboration with Celgene in October
The policy statement was informed by an FTC workshop held last year to examine how such drugs are marketed to consumers. The FTC also released its staff report
The financing from a single family office that is an existing investor includes the sale of a $1 million convertible note and up to $10 million in future equity
MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb clinical trial for moderate-to-severe Crohn’s disease and ready for Phase II for ulcerative colitis, diseases that sit
APX001 has received orphan drug designation for four distinct indications: the treatment of invasive candidiasis, invasive aspergillosis, coccidioidomycosis, and rare mold infections caused by Scedosporium spp., Fusarium spp.,
har Pharmaceuticals focused on transforming IV-only drugs into oral drugs for existing and new indications using its proprietary technology EnhanceTM development platform. With this acquisition, Grünenthal has obtained